Skip to main content
SpringerLink
Log in

HIV Protease Inhibitors in Pregnancy

Pharmacology and Clinical Use

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The impact of antiretroviral therapy (ART) on the natural history of HIV-1 infection has resulted in dramatic reductions in disease-associated morbidity and mortality. Additionally, the epidemiology of HIV-1 infection worldwide is changing, as women now represent a substantial proportion of infected adults. As more highly effective and tolerable antiretroviral regimens become available, and as the prevention of mother-to-child transmission becomes an attainable goal in the management of HIV-infected individuals, more and more HIV-positive women are choosing to become pregnant and have children. Consequently, it is important to consider the efficacy and safety of antiretroviral agents in pregnancy. Protease inhibitors are a common class of medication used in the treatment of HIV-1 infection and are increasingly being used in pregnancy. However, several studies have raised concerns regarding pharmacokinetic alterations in pregnancy, particularly in the third trimester, which results in suboptimal drug concentrations and a theoretically higher risk of virologic failure and perinatal transmission. Drug level reductions have been observed with each individual protease inhibitor and dose adjustments in pregnancy are suggested for certain agents. Furthermore, studies have also raised concerns regarding the safety of protease inhibitors in pregnancy, particularly as they may increase the risk of pre-term birth and metabolic disturbances. Overall, protease inhibitors are safe and effective for the treatment of HIV-infected pregnant women. Specifically, ritonavir-boosted lopinavir- and atazanavir-based regimens are preferred in pregnancy, while ritonavir-boosted darunavir- and saquinavir-based therapies are reasonable alternatives. This paper reviews the use of protease inhibitors in pregnancy, focusing on pharmacokinetic and safety considerations, and outlines the recommendations for use of this class of medication in the HIV-1-infected pregnant woman.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60.

    Article  PubMed  Google Scholar 

  2. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293–9.

    Article  Google Scholar 

  3. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr. 2010;53(1):124–30.

    Article  PubMed  Google Scholar 

  4. Mahy M, Stover J, Stanecki K, Stoneburner R, Tassie JM. Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults. Sex Transm Infect. 2010;86(Suppl. 2):ii67–71.

    Article  PubMed  Google Scholar 

  5. Kasamba I, Baisley K, Mayanja BN, Maher D, Grosskurth H. The impact of antiretroviral treatment on mortality trends of HIV-positive adults in rural Uganda: a longitudinal population-based study, 1999–2009. Trop Med Int Health. 2012;17(8):e66–73.

    Article  PubMed  Google Scholar 

  6. UNAIDS. UNAIDS report on the global AIDS epidemic 2010. The Joint United Nations Programme on HIV/AIDS [online]. (2010). http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf. Accessed 1 July 2012.

  7. Public Health Agency of Canada. HIV/AIDS Epi Updates, July 2010. Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2010.

  8. Public Health Agency of Canada. HIV and AIDS in Canada. Surveillance report to December 31, 2009. Ottawa: Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2010.

  9. Centers for Disease Control and Prevention. HIV in the United States: at a glance. Division of HIV/AIDS Prevention; National Centre for HIV/AIDS, Viral Hepatitis, STD and TB Prevention; US Department of Health and Human Services [online]. (2012). http://www.cdc.gov/hiv/resources/factsheets/PDF/HIV_at_a_glance.pdf. Accessed 21 Sep 2012.

  10. Ogilvie GS, Palepu A, Remple VP, et al. Fertility intentions of women of reproductive age living with HIV in British Columbia, Canada. AIDS. 2007;21(Suppl. 1):583–8.

    Google Scholar 

  11. Loutfy MR, Hart TA, Mohammed SS, Fertility Research Team, et al. Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study. PLoS ONE. 2009;4(12):e7925.

    Article  PubMed  CAS  Google Scholar 

  12. Chen JL, Philips KA, Kanouse DE, Collins RL, Miu A. Fertility desires and intentions of HIV-positive men and women. Fam Plann Perspect. 2001;33(4):144–52.

    Article  PubMed  CAS  Google Scholar 

  13. Bongain A, Berrebi A, Marine-Barjoan E, Dunais B, Thene M, Pradier C, et al. Changing trends in pregnancy outcome among HIV-infected women between 1985 and 1997 in two southern French university hospitals. Eur J Obstet Gynecol Reprod Biol. 2002;104(2):124–8.

    Article  PubMed  CAS  Google Scholar 

  14. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990–2006. BJOG. 2008;115(9):1078–86.

    Article  PubMed  CAS  Google Scholar 

  15. Cooper D, Harries J, Myer L, Orner P, Bracken H, Zweigenthal V. “Life is still going on”: reproductive intentions among HIV-positive women and men in South Africa. Soc Sci Med. 2007;65(2):274–83.

    Article  PubMed  Google Scholar 

  16. Firth J, Wang CC, Gillani F, Alexander N, Dufort E, Rana A, et al. The changing face of HIV in pregnancy in Rhode Island 2004–2009. Infect Dis Obstet Gynecol. 2012;2012:895047.

    Article  PubMed  Google Scholar 

  17. Fauci AS, Lane HC. Human Immunodeficiency Virus: AIDS and related disorders. In Kasper DL, Fauci AS, Longo DL, et al, editors. Harrison’s principles of internal medicine, 16th ed. New York (NY): McGraw-Hill; 2005. p. 1082–1083.

  18. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants; recommendations for a public health approach. The World Health Organization [online]. (2010). http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf. Accessed 1 Jul 2012.

  19. Burdge DR, Money DM, Forbes JC, et al. Canadian consensus guidelines for the management of pregnant HIV-positive women and their offspring. Can Med Assoc J. 2003;168(13):1683–8.

    Google Scholar 

  20. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–80.

    Article  PubMed  CAS  Google Scholar 

  21. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States [online]. (2012). http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. Accessed 21 Sept 2012.

  22. Loutfy MR, Margolese S, Money DR, et al. Canadian HIV pregnancy planning guidelines. J Obstet Gynaecol Can. 2010;34(6):575–90.

    Google Scholar 

  23. Taylor GP, Clayden P, Dhar J, Gandhi K, Gilleece Y, Harding K. The British HIV Association guidelines for the management of HIV infection in pregnant women 2012. HIV Med. 2012;13(Suppl. 2):87–157.

    Article  PubMed  Google Scholar 

  24. European AIDS Clinical Society. European guidelines for the treatment of HIV-infected adults in Europe [online]. (2011). http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6.0-English.pdf. Accessed 15 Aug 2012.

  25. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354(9181):795–802.

    Article  PubMed  CAS  Google Scholar 

  26. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011; 7(CD003510).

  27. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29(5):484–94.

    PubMed  CAS  Google Scholar 

  28. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra Study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359(9313):1178–86.

    Article  Google Scholar 

  29. Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, Kinuthia J, et al. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast-milk HIV type-1 RNA: a phase II randomized clinical trial. Antivir Ther. 2008;13(6):799–807.

    PubMed  CAS  Google Scholar 

  30. Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora Study): a randomised controlled trial. Lancet Infect Dis. 2011;11(3):171–80.

    Article  CAS  Google Scholar 

  31. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362(24):2282–94.

    Article  PubMed  CAS  Google Scholar 

  32. Loutfy MR, Raboud JM, Wong J, Yudin MH, Diong C, Blitz SL, et al. High prevalence of unintended pregnancies in HIV-positive women of reproductive age in Ontario, Canada: a retrospective study. HIV Med. 2012;13:107–17.

    Article  PubMed  Google Scholar 

  33. Schwartz SR, Rees H, Mehta S, Venter WDF, Taha TE, Black V. High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa. PLoS One. 2012;7(4):e36039.

    Article  PubMed  CAS  Google Scholar 

  34. Floridia M, Ravizza M, Guaraldi G, Pinnetti C, Martinelli P, Tamburrini E. Use of specific antiretroviral regimens among HIV-infected women in Italy at time of conception: 2001–2011. AIDS Patient Care STDS. 2012;26(8):439–43.

    Article  PubMed  Google Scholar 

  35. Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis. 2001;183(4):539–45.

    Article  PubMed  CAS  Google Scholar 

  36. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States [online]. (2006). http://aidsinfo.nih.gov/contentfiles/PerinatalGL000616.pdf Accessed 30 May 2012.

  37. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States [online]. (2005). http://aidsinfo.nih.gov/ContentFiles/PerinatalGL02242005027.pdf. Accessed 30 May 2012.

  38. Griner R, Williams PL, Read JS, Seage GR III, Crain M, Yogev R, et al. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS. 2011;25(7):385–94.

    Article  PubMed  Google Scholar 

  39. Baroncelli S, Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, et al. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patters, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS. 2009;23(7):513–20.

    Article  PubMed  Google Scholar 

  40. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004;35(5):538–9.

    Article  PubMed  Google Scholar 

  41. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of non-nucleoside reverse transcriptase inhibitors. Clin Infect Dis. 2004;38(Suppl. 2):S80–9.

    Article  PubMed  CAS  Google Scholar 

  42. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 January 1989 through 31 January 2012. Wilmington (NC): Registry Coordinating Centre [online]. (2012). www.APRegistry.com. Accessed 15 Aug 2012.

  43. Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS. 2010;24(10):1461–70.

    Article  PubMed  CAS  Google Scholar 

  44. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first-trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25(18):2301–4.

    Article  PubMed  CAS  Google Scholar 

  45. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Aruduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.

    Article  PubMed  CAS  Google Scholar 

  46. Saada M, Le Chenadec J, Berrebi A, et al. Pregnancy and progression to AIDS: results of the French prospective cohorts. AIDS. 2000;14:2355–60.

    Article  PubMed  CAS  Google Scholar 

  47. Stek AM. Antiretroviral medications during pregnancy for therapy or prophylaxis. Curr HIV/AIDS Rep. 2009;6:68–76.

    Article  PubMed  Google Scholar 

  48. Shannon M. Antiretroviral therapy in HIV-infected pregnant women and their infants: current interventions and challenges. J Perinat Neonat Nurs. 2002;16(2):1–25.

    Google Scholar 

  49. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine and lamivudine. AIDS. 2007;21:643–7.

    Article  PubMed  CAS  Google Scholar 

  50. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20:1931–9.

    Article  PubMed  CAS  Google Scholar 

  51. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43(15):1071–87.

    Article  PubMed  CAS  Google Scholar 

  52. Ghosn J, De Montgolfier I, Cornelie C, et al. Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy. Antimicrob Agents Chemother. 2008;52(4):1542–4.

    Article  PubMed  CAS  Google Scholar 

  53. van der Lugt J, Colbers A, Burger D. Clinical pharmacology of HIV protease inhibitors in pregnancy. Curr Opin HIV/AIDS. 2008;3:620–6.

    Article  Google Scholar 

  54. Acosta EP, Bardeguez A, Zorrilla CD, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004;48(2):430–6.

    Article  PubMed  CAS  Google Scholar 

  55. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997;33(5):328–43.

    Article  PubMed  CAS  Google Scholar 

  56. Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1 infected pregnant and non-pregnant women. Br J Clin Pharmacol. 2006;62(3):309–15.

    Article  PubMed  CAS  Google Scholar 

  57. Bryson YJ, Mirochnick M, Stek AM, et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials. 2008;9(2):115–25.

    Article  PubMed  CAS  Google Scholar 

  58. Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011;56(5):412–9.

    Article  PubMed  CAS  Google Scholar 

  59. Weinberg A, Harwood JEF, McFarland EJ, et al. Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol. 2009;2009:621780.

    Article  PubMed  CAS  Google Scholar 

  60. Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2007;51(2):783–6.

    Article  PubMed  CAS  Google Scholar 

  61. Hirt D, Treluyer J, Jullien V, et al. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrob Agents Chemother. 2006;50(6):2079–86.

    Article  PubMed  CAS  Google Scholar 

  62. van Heeswijk RPG, Khaliq Y, Gallicano KD, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post-partum. Clin Pharmacol Ther. 2004;76:588–97.

    Article  PubMed  CAS  Google Scholar 

  63. Nellen JF, Schillevoort I, Wit F, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis. 2004;39:736–40.

    Article  PubMed  CAS  Google Scholar 

  64. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP 1A2, CYP2D6 and CYP3A4 activity) during pregnancy. Am J Obstet Gynecol. 2005;192:633–9.

    Article  PubMed  CAS  Google Scholar 

  65. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, et al. Transplacental passage of protease inhibitors at delivery. AIDS. 2002;16:889–93.

    Article  PubMed  CAS  Google Scholar 

  66. Chappuy H, Treluyer JM, Rey E, Dimet J, Fouche M, Firtion G, et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol. 2004;191(2):558–62.

    Article  PubMed  CAS  Google Scholar 

  67. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J. 2002;21:835–8.

    Article  PubMed  Google Scholar 

  68. Zorrilla CD, Van Dyke R, Bardeguez A, et al. Clinical response and tolerability to and safety of saquinavir with low- dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrob Agents Chemother. 2007;51(6):2208–10.

    Article  PubMed  CAS  Google Scholar 

  69. Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS. 2007;21:2409–15.

    Article  PubMed  CAS  Google Scholar 

  70. Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011;56(5):412–9.

    Article  PubMed  CAS  Google Scholar 

  71. Ripamonti D, Cattaneo D, Cortinovis M, Maggiolo F, Suter F. Transplacental passage of ritonavir-boosted darunavir in two pregnant women. Int J STD AIDS. 2009;20(3):215–6.

    Article  PubMed  CAS  Google Scholar 

  72. van Hoog S, Boer K, Nellen J, Scherpbier H, Godfried MH. Transplacental passage of nevirapine, nelfinavir and lopinavir. Neth J Med. 2012;70(2):102–3.

    PubMed  Google Scholar 

  73. Watts DH. Management of human immunodeficiency virus infection in pregnancy. N Engl J Med. 2002;346(24):1879–91.

    Article  PubMed  CAS  Google Scholar 

  74. Covington DL, Conner SD, Doi PA, Swinson J, Daniels EM. Risk of birth defects associated with nelfinavir exposure during pregnancy. Obstet Gynecol. 2004;103(6):1181–9.

    Article  PubMed  CAS  Google Scholar 

  75. Townsend CL, Tookey PA, Cortina-Borja M, Peckham CS. Antiretroviral therapy and congenital abnormalities in infants born to HIV-1-infected women in the United Kingdom and Ireland, 1990 to 2003. J Acquir Immune Defic Syndr. 2006;42:91–4.

    Article  PubMed  Google Scholar 

  76. Watts DH, Covington DL, Beckerman K, Garcia P, Scheuerle A, Dominguez Z, et al. Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol. 2004;191(3):985–92.

    Article  PubMed  CAS  Google Scholar 

  77. Szyld EG, Warley EM, Freimanis L, Gonin R, Cahn PE, Calvet GA, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS. 2006;20:2345–53.

    Article  PubMed  Google Scholar 

  78. Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449–73.

    Article  PubMed  CAS  Google Scholar 

  79. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346(24):1863–70.

    Article  PubMed  Google Scholar 

  80. Cotter AM, Garcia AG, Duthely ML, Luke B, O’Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193(9):1195–201.

    Article  PubMed  CAS  Google Scholar 

  81. Morris AB, Cu-Uvin S, Harwell JI, Garb J, Zorrilla C, Vajaranant M, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr. 2000;25:306–11.

    Article  PubMed  CAS  Google Scholar 

  82. El Beitune P, Duarte G. Antiretroviral agents during pregnancy: consequences in hematologic parameters in HIV-exposed, uninfected newborn infant. Eur J Obstet Gynecol Reprod Biol. 2006;128:59–63.

    Article  PubMed  CAS  Google Scholar 

  83. Bellon Cano JM, Sanchez-Ramon S, Ciria L, Leon JA, Gurbindo D, Fortuny C, et al. The effects on infants of potent antiretroviral therapy during pregnancy: a report from Spain. Med Sci Monit. 2004;10(5):CR179–84.

    PubMed  Google Scholar 

  84. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS. 1998;12:F241–7.

    Article  PubMed  CAS  Google Scholar 

  85. European Collaborative Study and the Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14:2913–2920.

    Google Scholar 

  86. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:380–7.

    Article  Google Scholar 

  87. Sibiude J, Warszawski J, Tubiana R, Dollfus C, Faye A, Rouzioux C, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?. Clin Infect Dis. 2012;54(9):1348–60.

    Article  PubMed  CAS  Google Scholar 

  88. Thorne C, Patel D, Newell ML. for the European Collaborative Study. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18:2337–9.

    Article  PubMed  Google Scholar 

  89. Rudin C, Spaenhauer A, Keiser O, Rickenbach M, Kind C, Aebi-Popp K, et al. Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data. HIV Med. 2010;12:228–35.

    Article  PubMed  CAS  Google Scholar 

  90. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21:1019–26.

    Article  PubMed  Google Scholar 

  91. Martin F, Taylor GP. Increased rates of preterm delivery are associated with initiation of highly active antiretroviral therapy during pregnancy: a single centre cohort study. J Infect Dis. 2007;196:558–61.

    Article  PubMed  CAS  Google Scholar 

  92. Centres for Disease Control and Prevention, U.S. Public Health Service Task Force. U.S. Public Health Service Task Force Recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep. 2002;51(RR-18):1–38.

    Google Scholar 

  93. Dinsmoor MJ, Forrest ST. Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy. Infect Dis Obstet Gynecol. 2002;10:187–91.

    Article  PubMed  Google Scholar 

  94. Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek AM, Bardeguez AD, et al. Antenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretrovirals during pregnancy. J Infect Dis. 2010;210(7):1035–44.

    Article  CAS  Google Scholar 

  95. Carceller A, Ferreira EM, Alloul S, Lapointe N. Lack of effect on prematurity, birth weight and infant growth from exposure to protease inhibitors in utero and after birth. Pharmacotherapy. 2009;29(11):1289–96.

    Article  PubMed  CAS  Google Scholar 

  96. Watts DH, Balasubramanian R, Maupin RT Jr, Delke I, Dorenbaum A, Fiore S, et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol. 2004;190:506–15.

    Article  PubMed  CAS  Google Scholar 

  97. Culnane M, Fowler MG, Lee S, McSherry G, Brady M, O’Donnell K, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. PACTG 219/076 teams. JAMA. 1999;281:151–7.

    Article  PubMed  CAS  Google Scholar 

  98. Townsend CL, Schulte J, Thorne C, Dominguez KL, Tookey PA, Cortina-Borja, et al. Antiretroviral therapy and preterm delivery: a pooled analysis of data from the United States and Europe. BJOG. 2010;117:1399–410.

    Article  PubMed  Google Scholar 

  99. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21:607–15.

    Article  PubMed  CAS  Google Scholar 

  100. Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG. Pediatric Spectrum of HIV Disease Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989–2004. Pediatrics. 2007;119(4):e900–6.

    Article  PubMed  Google Scholar 

  101. Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, van Widenfelt E, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204:506–14.

    Article  PubMed  CAS  Google Scholar 

  102. Machado ES, Hofer CB, Costa TT, Nogueira SA, Oliveira RH, Abreu TF, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before pregnancy versus after conception. Sex Transm Infect. 2009;85(2):82–7.

    Article  PubMed  CAS  Google Scholar 

  103. Boer K, Nellen JF, Patel D, Timmermans S, Tempelman C, Wibaut M, et al. The Am-Ro Study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG. 2007;114(2):148–55.

    Article  PubMed  CAS  Google Scholar 

  104. Grosch-Woerner I, Puch K, Maier RF, Niehues T, Notheis G, Patel D, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med. 2008;9:6–13.

    Article  PubMed  CAS  Google Scholar 

  105. Watts DH, Williams PL, Kacanek D, Griner R, Rich K, Hazra R, et al. Combination antiretroviral use and preterm birth. J Infect Dis. 2013. [Epub ahead of print].

  106. Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, Faye A, et al. No relation between in-utero exposure to HARRT and intrauterine growth retardation. AIDS. 2009;23:1235–43.

    Article  PubMed  CAS  Google Scholar 

  107. Dola CP, Khan R, DeNicola N, Amirgholami M, Benjamin T, Bhuiyan A, et al. Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy. J Perinat Med. 2012;40:51–5.

    Article  CAS  Google Scholar 

  108. Morris AB, Dobles AR, Cu-Uvin S, Zorrilla C, Anderson J, Harwell JI, et al. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr. 2005;40(1):30–3.

    Article  PubMed  CAS  Google Scholar 

  109. Fiore S, Ferrazzi E, Newell M, Trabattoni D, Clerici M. Protease inhibitor-associated increased risk of preterm delivery is an immunological complication of therapy. J Infect Dis. 2007;195:914–6.

    Article  PubMed  Google Scholar 

  110. Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, Czernichow P. Adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA. 2011;306(1):70–8.

    Article  PubMed  CAS  Google Scholar 

  111. Goldenberg RL, Culhane JF, Iams JD, Romera R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75–84.

    Article  PubMed  Google Scholar 

  112. American College of Obstetrics and Gynecologists. Gestational Diabetes Practice Bulletin 30; September 2001.

  113. Chmait R, Franklin P, Spector SA, Hull AD. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinatol. 2002;22:370–3.

    Article  PubMed  Google Scholar 

  114. Hitti J, Andersen J, McComsey G, Liu T, Melvin A, Smith L, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol. 2007;196(4):331.e1–7.

    Google Scholar 

  115. Tang JH, Sheffield JS, Grimes J, McElwee B, Roberts SW, Laibl V, et al. Effect of protease inhibitor therapy on glucose tolerance in pregnancy. Obstet Gynecol. 2006;107:1115–9.

    Article  PubMed  CAS  Google Scholar 

  116. Abbott Laboratories. Kaletra® (lopinavir/ritonavir): highlights of prescribing information (package insert). (2012).

  117. Khuong-Josses MA, Azerad D, Boussaiiri A, Ekoukou D. Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women. HIV Clin Trials. 2007;8(4):254–5.

    Article  PubMed  Google Scholar 

  118. Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010;54(4):381–8.

    PubMed  CAS  Google Scholar 

  119. Bouillon-Pichault M, Jullien V, Azria E, Pannier E, Firtion G, Krivine A, et al. Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Ther. 2009;63:1223–32.

    Article  CAS  Google Scholar 

  120. Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, et al. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS. 2010;24(14):2193–200.

    Article  PubMed  CAS  Google Scholar 

  121. Lambert JS, Else LJ, Jackson V, Breiden J, Gibbons S, Dickinson L, et al. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med. 2011;12:166–73.

    Article  PubMed  CAS  Google Scholar 

  122. Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett S, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008;49(5):485–91.

    Article  PubMed  Google Scholar 

  123. Roberts SS, Martinez M, Covington DL, Rode RA, Pasley MV, Woodward W. Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr. 2009;51(4):456–61.

    Article  PubMed  CAS  Google Scholar 

  124. Dhondt JL, Dorche C, Farriaux JP, Courte C. Neonatal screening for congenital adrenal hyperplasia: a pilot study in France. J Inherit Metab Dis. 1986;9(Suppl. 1):147–51.

    Article  PubMed  Google Scholar 

  125. Bristol-Myers Squibb. Reyataz® (atazanavir sulfate): highlights of prescribing information (package insert). (2012).

  126. Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med. 2011;12:570–9.

    Article  PubMed  CAS  Google Scholar 

  127. U.S. Food and Drug Administration. Reyataz (atazanavir) label revised, adding dosing recommendations for pregnancy and postpartum period [online]. (2011). http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm242383.htm. Accessed 15 Aug 2012.

  128. Mandelbrot L, Mazy F, Floch-Tudal C, Meier F, Azria E, Crenn-Hebert, et al. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. Eur J Obstet Gynecol. 2011;157:18–21.

    Article  CAS  Google Scholar 

  129. Tibotec. Prezista® (darunavir): highlights of prescribing information (package insert). (2012).

  130. Sued O, Lattner J, Gun A, Patterson P, Abusamra L, Cesar C, et al. Use of darunavir and enfuvirtide in a pregnant woman. Int J STD AIDS. 2008;19:866–7.

    Article  PubMed  CAS  Google Scholar 

  131. Ivanovic J, Bellagamba R, Nicastri E, Signore F, Vallone C, Tempestilli M, et al. Use of darunavir/ritonavir once daily in treatment-naïve pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS. 2010;24:1083–4.

    Article  PubMed  Google Scholar 

  132. Pacanowski J, Bollens D, Poirier JM, Morand-Joubert L, Castaigne V, Girard PM, et al. Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient. AIDS. 2009;23:1923–4.

    Article  PubMed  Google Scholar 

  133. Jaworsky D, Thompson C, Yudin MH, Bitnun A, Brophy J, Samson L, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther. 2010;15(4):677–80.

    Article  PubMed  CAS  Google Scholar 

  134. Capparelli EV, Best BM, Stek A, et al. Pharmacokinetics of darunavir once or twice daily during pregnancy and postpartum [abstract no. P72]. In: 3rd International workshop on HIV pediatrics; 15–16 July 2011; Rome.

  135. Colbers A, Taylor G, Molto J, Ivanovic J, Wyen C, Schwarze-Zander C, et al. A comparison of the pharmacokinetics of tenofovir during pregnancy and postpartum [abstract no. P34]. In: 13th International workshop on clinical pharmacology of HIV therapy; 16–18 April 2012; Barcelona.

  136. Zorrilla C, Wright R, Osiyemi O, Yasin S, Baugh B, Brown K, et al. Total and unbound darunavir pharmacokinetics in HIV-1+ pregnant women [abstract no. 1012]. In: 19th Conference on retroviruses and opportunistic infections (CROI); March 5–8, 2012; Seattle (WA).

  137. Furco A, Gosrani B, Nicholas S, Williams A, Braithwaite W, Pozniak A, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS. 2009;23:434–5.

    Article  PubMed  Google Scholar 

  138. Genetech. Invirase® (saquinavir mesylate): highlights of prescribing information (package insert). (2012).

  139. La Porte CJL. Saquinavir, the pioneer antiretroviral protease inhibitor. Exp Opin Drug Metab Toxicol. 2009;5(10):1313–22.

    Article  CAS  Google Scholar 

  140. Vithayasai V, Moyle GJ, Supajatura V, Wattanatchariya N, Kanshana S, Sirichthaporn P, et al. Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optimal lamivudine in pregnancy and prevention of vertical HIV transmission. J Acquir Immune Defic Syndr. 2002;30:410–2.

    PubMed  CAS  Google Scholar 

  141. Acosta EP, Zorrilla C, Van Dyke R, Bardeguez A, Smith E, Hughes M, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials. 2001;2(6):460–5.

    Article  PubMed  CAS  Google Scholar 

  142. Lopes-Cortes LF, Ruiz-Valderas R, Pascual R, Rodriguez M, Marin A. Once daily saquinavir-HGC plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy. HIV Clin Trials. 2003;4(3):227–9.

    Article  Google Scholar 

  143. Hanlon M, O’Dea S, Clarke S, et al. Maternal hepatotoxicity with boosted saquinavir as part of combination ART in pregnancy [abstract no. 753]. In: 14th Conference on retroviruses and opportunistic infections (CROI); 25–28 February 2007; Los Angeles (CA).

  144. Merck Canada Inc. Crixivan® (indinavir sulfate): drug monograph. (2012).

  145. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS. 2003;17:1195–9.

    Article  PubMed  CAS  Google Scholar 

  146. Quintino MP, Nakamura MU, de Jesus Simoes M, Araujo Junior E, de Oliveira Filho RM, Torloni MR, et al. Chronic use of indinavir in albino rat pregnancy (Rattus Norvegicus Albinus, Rodentia, Mammalia): biological assay. J Obstet Gynecol Res. 2011;37(9):1212–5.

    Article  CAS  Google Scholar 

  147. Pfizer Canada. Viracept® (nelfinavir mesylate): drug monograph. (2011).

  148. Read JS, Best BM, Stek AM, Capparelli EV, Holland DT, Burchett SK, et al. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008;9(10):875–82.

    PubMed  CAS  Google Scholar 

  149. Montserrat O, Podzamczer D. A review of nelfinavir for the treatment of HIV infection. Exp Opin Drug Metab Toxicol. 2006;2(2):285–300.

    Article  Google Scholar 

  150. Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005;19:795–9.

    Article  PubMed  CAS  Google Scholar 

  151. European Medicines Agency. European Medicines Agency announces recall of viracept [media release]. 6 June 2007 [online]. (2007). http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500014207.pdf. Accessed 3 Dec 2012.

  152. European Medicines Agency. CHMP assessment report for viracept [online]. (2007). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000164/WC500050681.pdf. Accessed 3 Dec 2012.

  153. Health Canada. Important safety information on viracept® (nelfinavir mesylate); for health care professionals [online]. (2007). http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2007/viracept_hpc-cps-eng.php. Accessed 15 Aug 2012.

  154. Health Canada. Health Canada determines viracept® (nelfinavir mesylate) can be used again in non-pregnant HIV-infected adults and children [media release]. 12 August 2008 [online]. (2008). http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2008/2008_144-eng.php. Accessed 15 Aug 2012.

  155. ViiV Healthcare. Telzir® (fosamprenavir calcium): drug monograph. (2011).

  156. Capparelli EV, Stek A, Best B, et al. Boosted fosamprenavir pharmacokinetics during pregnancy [abstract no. 908]. In: 17th Conference on retroviruses and opportunistic infections (CROI); 16–19 February 2010; San Francisco (CA).

  157. Martorell C, Theroux E, Bermudez A, Garb J, Kronschnabel D, Oie K. Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women. Ped Infect Dis J. 2010;29(10):985.

    Article  Google Scholar 

  158. Boehringer Ingelheim. Aptivus® (tipranavir): highlights of prescribing information (package insert). (2012).

  159. Weizsaecker K, Kurowski M, Hoffmeister B, Schurmann D, Feiterna-Sperling C. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. Int J STD AIDS. 2011;22:294–5.

    Article  PubMed  CAS  Google Scholar 

  160. Wensing AMJ, Boucher CAB, van Kasteren M, van Dijken PJ, Geelen SP, Juttman JR. Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. AIDS. 2006;20:1465–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Toronto, Toronto, ON, Canada

    Nisha Andany & Mona R. Loutfy

  2. Women’s College Research Institute, Women’s College Hospital, Toronto, ON, Canada

    Mona R. Loutfy

  3. 790 Bay Street, 7th Floor, Toronto, ON, M5G 1N8, Canada

    Mona R. Loutfy

Authors
  1. Nisha Andany
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mona R. Loutfy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mona R. Loutfy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andany, N., Loutfy, M.R. HIV Protease Inhibitors in Pregnancy. Drugs 73, 229–247 (2013). https://doi.org/10.1007/s40265-013-0017-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0017-3

Keywords

Search

Navigation